[Effect of ligustrazine on plasma lipid peroxidation, superoxide dismutase of the coronary heart disease]. 1994

G H Fan, and C Q Xiao, and J M Chen
163rd Hospital of PLA, Changsha.

A clinical study on 59 remote myocardial infarction cases were divided randomly into treated group (31 cases) and normal control group (28 cases). Treated group used intravenously injected Ligustrazine 160 mg a day for 10 days. The plasma lipid peroxidation (LPO), superoxide dismutase (SOD) and sulfhydryl group were measured before and after treatment in the treated group, in comparing with normal control group. The results showed the levels of LPO significantly reduced (P < 0.01), and SOD, sulfhydryl group was obviously increased after Ligustrazine administration (P < 0.05). Attack of angina pectoris was reduced. Between these two group, the difference was significant (P < 0.05). Mechanism of Ligustrazine in reducing LPO and increasing SOD could be the inhibiting of platelet aggregation, regulating the TXA2/PGI2 ratio in plasma, protecting myocardial cell membrane and improving the myocardial ischemia. Ligustrazine could reduce the production of LPO due to the accelerating clearance of oxygen free radical.

UI MeSH Term Description Entries
D008054 Lipid Peroxides Peroxides produced in the presence of a free radical by the oxidation of unsaturated fatty acids in the cell in the presence of molecular oxygen. The formation of lipid peroxides results in the destruction of the original lipid leading to the loss of integrity of the membranes. They therefore cause a variety of toxic effects in vivo and their formation is considered a pathological process in biological systems. Their formation can be inhibited by antioxidants, such as vitamin E, structural separation or low oxygen tension. Fatty Acid Hydroperoxide,Lipid Peroxide,Lipoperoxide,Fatty Acid Hydroperoxides,Lipid Hydroperoxide,Lipoperoxides,Acid Hydroperoxide, Fatty,Acid Hydroperoxides, Fatty,Hydroperoxide, Fatty Acid,Hydroperoxide, Lipid,Hydroperoxides, Fatty Acid,Peroxide, Lipid,Peroxides, Lipid
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D010975 Platelet Aggregation Inhibitors Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. Antiaggregants, Platelet,Antiplatelet Agent,Antiplatelet Agents,Antiplatelet Drug,Blood Platelet Aggregation Inhibitor,Blood Platelet Antagonist,Blood Platelet Antiaggregant,PAR-1 Antagonists,Platelet Aggregation Inhibitor,Platelet Antagonist,Platelet Antagonists,Platelet Antiaggregant,Platelet Antiaggregants,Platelet Inhibitor,Protease-Activated Receptor-1 Antagonists,Antiplatelet Drugs,Blood Platelet Aggregation Inhibitors,Blood Platelet Antagonists,Blood Platelet Antiaggregants,Platelet Inhibitors,Agent, Antiplatelet,Aggregation Inhibitor, Platelet,Antagonist, Blood Platelet,Antagonist, Platelet,Antiaggregant, Blood Platelet,Antiaggregant, Platelet,Drug, Antiplatelet,Inhibitor, Platelet,Inhibitor, Platelet Aggregation,PAR 1 Antagonists,Platelet Antagonist, Blood,Platelet Antiaggregant, Blood,Protease Activated Receptor 1 Antagonists
D011719 Pyrazines A heterocyclic aromatic organic compound with the chemical formula C4H4N2. Pyrazine
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D013438 Sulfhydryl Compounds Compounds containing the -SH radical. Mercaptan,Mercapto Compounds,Sulfhydryl Compound,Thiol,Thiols,Mercaptans,Compound, Sulfhydryl,Compounds, Mercapto,Compounds, Sulfhydryl

Related Publications

G H Fan, and C Q Xiao, and J M Chen
May 1996, Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine,
G H Fan, and C Q Xiao, and J M Chen
May 2001, Chemistry and physics of lipids,
G H Fan, and C Q Xiao, and J M Chen
November 1996, Research communications in molecular pathology and pharmacology,
G H Fan, and C Q Xiao, and J M Chen
January 1980, Voprosy meditsinskoi khimii,
G H Fan, and C Q Xiao, and J M Chen
April 1995, Biochemistry and molecular biology international,
G H Fan, and C Q Xiao, and J M Chen
December 1990, Burns : journal of the International Society for Burn Injuries,
G H Fan, and C Q Xiao, and J M Chen
December 1998, Annals of the New York Academy of Sciences,
G H Fan, and C Q Xiao, and J M Chen
January 1995, Contributions to nephrology,
G H Fan, and C Q Xiao, and J M Chen
July 1983, Biokhimiia (Moscow, Russia),
Copied contents to your clipboard!